-
Tytuł:
-
Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study.
-
Autorzy:
-
Bsteh G; Department of Neurology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.; Department of Neurology, Medical University of Vienna, Vienna, Austria.
Dürauer S; Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria.
Assar H; Department of Neurology, Kepler University Hospital, Linz, Austria.
Hegen H; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Heschl B; Department of Neurology, Medical University of Graz, Graz, Austria.
Leutmezer F; Department of Neurology, Medical University of Vienna, Vienna, Austria.
Pauli FD; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Gradl C; Department of Neurology, Medical University of St. Pölten, St. Pölten, Austria.
Traxler G; Department of Neurology 2, Med Campus III, Kepler University Hospital GmbH, Linz, Austria.
Zulehner G; Department of Neurology, Medical University of Vienna, Vienna, Austria.
Rommer P; Department of Neurology, Medical University of Vienna, Vienna, Austria.
Wipfler P; Department of Neurology, Paracelsus Medical University of Salzburg, Salzburg, Austria.
Guger M; Department of Neurology 2, Med Campus III, Kepler University Hospital GmbH, Linz, Austria.
Höftberger R; Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria.
Enzinger C; Department of Neurology, Medical University of Graz, Graz, Austria.
Berger T; Department of Neurology, Medical University of Vienna, Vienna, Austria.
-
Źródło:
-
Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2021 Dec; Vol. 27 (14), pp. 2209-2218. Date of Electronic Publication: 2021 Oct 01.
-
Typ publikacji:
-
Journal Article; Research Support, Non-U.S. Gov't
-
Język:
-
English
-
Imprint Name(s):
-
Publication: 2006- : London : SAGE Publications
Original Publication: Houndmills, Basingstoke, Hampshire, UK : Stockton Press, c1995-
-
MeSH Terms:
-
COVID-19*
Multiple Sclerosis*/drug therapy
Adult ; Austria ; Female ; Humans ; Immunity, Humoral ; Male ; SARS-CoV-2
-
References:
-
JAMA Neurol. 2020 Sep 1;77(9):1079-1088. (PMID: 32589189)
Ther Adv Neurol Disord. 2021 Apr 22;14:17562864211012835. (PMID: 34035836)
Eur J Neurol. 2021 Oct;28(10):3384-3395. (PMID: 33340215)
Immunity. 2020 Jun 16;52(6):910-941. (PMID: 32505227)
Mult Scler Relat Disord. 2021 Feb;48:102698. (PMID: 33385826)
Mult Scler Relat Disord. 2021 May;50:102800. (PMID: 33578206)
Neurology. 2020 Jun 2;94(22):949-952. (PMID: 32241953)
Neurol Neuroimmunol Neuroinflamm. 2020 May 15;7(4):. (PMID: 32414755)
Ann Neurol. 2005 Dec;58(6):840-6. (PMID: 16283615)
Lancet Neurol. 2018 Feb;17(2):162-173. (PMID: 29275977)
Wien Klin Wochenschr. 2021 Apr;133(7-8):351-358. (PMID: 33315138)
Ann Neurol. 2011 Feb;69(2):292-302. (PMID: 21387374)
Clin Exp Immunol. 2020 Nov;202(2):149-161. (PMID: 32671831)
J Clin Med. 2020 Dec 16;9(12):. (PMID: 33339436)
Eur J Neurol. 2021 Oct;28(10):3369-3374. (PMID: 32978860)
Mult Scler Relat Disord. 2021 May;50:102793. (PMID: 33588315)
JAMA Neurol. 2021 Jul 1;78(7):880-882. (PMID: 33929488)
Sustain Prod Consum. 2021 Apr;26:343-359. (PMID: 33072833)
Mult Scler. 2022 Jun;28(7):1034-1040. (PMID: 34328824)
Mult Scler Relat Disord. 2021 Jul;52:103014. (PMID: 34000684)
PLoS One. 2021 Jul 27;16(7):e0255316. (PMID: 34314457)
Mult Scler. 2022 Jan;28(1):165-167. (PMID: 34387536)
Clin Microbiol Infect. 2021 Sep;27(9):1349.e1-1349.e6. (PMID: 33975009)
-
Contributed Indexing:
-
Keywords: COVID-19; Multiple sclerosis; SARS-CoV-2; antibody; disease-modifying treatment; humoral response; seropositivity
-
Entry Date(s):
-
Date Created: 20211001 Date Completed: 20211119 Latest Revision: 20231108
-
Update Code:
-
20240105
-
PubMed Central ID:
-
PMC8597187
-
DOI:
-
10.1177/13524585211049391
-
PMID:
-
34595968
-
Background: Knowledge on immunity after SARS-CoV-2 infection in patients with multiple sclerosis (pwMS) and the impact of disease-modifying treatment (DMT) is limited.
Objective: To evaluate degree, duration and potential predictors of specific humoral immune response in pwMS with prior COVID-19.
Methods: Anti-SARS-CoV-2 antibody testing was performed in pwMS with PCR-confirmed diagnosis of symptomatic COVID-19 from a nation-wide registry. Predictors of seropositivity were identified by multivariate regression models.
Results: In 125 pwMS (mean age = 42.4 years (SD = 12.3 years), 70% female), anti-SARS-CoV-2 antibodies were detected in 76.0% after a median of 5.2 months from positive PCR. Seropositivity rate was significantly lower in patients on IS-DMT (61.4%, p = 0.001) than without DMT or immunomodulatory DMT (80.6%; 86.0%, respectively). In multivariate analysis, IS-DMT was associated with reduced probability of seropositivity (odds ratio (OR): 0.51; 95% confidence interval (95% CI): 0.17-0.82; p < 0.001). Predefined subgroup analyses showed marked reduction of seropositivity in pwMS on rituximab/ocrelizumab (OR 0.15; 95% CI: 0.05-0.56; p < 0.001). Rate of seropositivity did not change significantly over 6 months.
Conclusions: Humoral immunity is stable after SARS-CoV-2 infection in MS, but is reduced by immunosuppressive DMT, particularly anti-CD20 monoclonal antibodies. This provides important evidence for advising pwMS as well as for planning and prioritizing vaccination.
